Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure

PHASE3CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 31, 2017

Study Completion Date

September 30, 2017

Conditions
HIV Infection
Interventions
DRUG

dolutegravir

50 mg tablet by mouth once daily for 48 weeks

DRUG

lamivudine

300 mg tablet by mouth once daily for 48 weeks

DRUG

Continue current antiretroviral regimen

Continue current DHHS recommended or alternative three-drug antiretroviral regimen

Trial Locations (7)

60611

Northwestern University, Chicago

Unknown

University of California San Diego, San Diego

Emory University, Atlanta

Brigham and Women's Hospital, Boston

Cornell University, New York

University of Cincinnati, Cincinnati

The Ohio State University, Columbus

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

lead

Babafemi Taiwo

OTHER